Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

MT Newswires Live

17小時前

Design Therapeutics (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.

The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.

The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.

The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.

Shares of the company were down 3.3% in recent trading.

Price: 4.70, Change: -0.16, Percent Change: -3.29

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532888223"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532888223\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2532888223?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532888223","market":"sg","top_or_hot":-1,"title":"Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'","media":"MT Newswires Live","content":"<html><body><p> Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.</p><p>The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.</p><p>The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.</p><p>The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.</p><p>Shares of the company were down 3.3% in recent trading.</p><p>Price: 4.70, Change: -0.16, Percent Change: -3.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDesign Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-02 00:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Design <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.</p><p>The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.</p><p>The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.</p><p>The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.</p><p>Shares of the company were down 3.3% in recent trading.</p><p>Price: 4.70, Change: -0.16, Percent Change: -3.29</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DSGN","symbol_name":"Design Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532888223","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532888223","pubTimestamp":1746116981,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Design Therapeutics  said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.Shares of the company were down 3.3% in recent trading.Price: 4.70, Change: -0.16, Percent Change: -3.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DSGN":"Design Therapeutics, Inc.","LENZ":"Therapeutics","BK4505":"高瓴资本持仓","BK4139":"生物科技","BK4539":"次新股","BK4007":"制药"},"translate_title":"Design Therapeutics表示治疗富克斯内皮角膜营养不良的滴眼液“耐受性良好”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DSGN":1,"LENZ":1},"content_text":"Design Therapeutics (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.Shares of the company were down 3.3% in recent trading.Price: 4.70, Change: -0.16, Percent Change: -3.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}